Relfydess Ready-to-Use Neurotoxin Hits a Second FDA Delay: What Vegas Clients Should Know
Galderma's ready-to-use neuromodulator is already sold in more than 20 countries, but the FDA just sent its U.S. application back a second time over manufacturing questions. Here is what the delay does and doesn't mean for your next appointment.
Key takeaways
- Galderma's relabotulinumtoxinA, branded Relfydess, just received a second FDA Complete Response Letter tied to manufacturing site observations, not to safety or effectiveness data.
- The product is already approved in roughly 33 countries and actively sold in more than 20 of them, so it isn't available for injections inside the United States yet.
- Established neuromodulators already cleared for U.S. use are unaffected by this news and remain available through licensed local providers.
- A regulatory setback for one product is a good reminder to ask any med spa exactly which FDA-cleared toxin or filler you're being offered before you book.
Figures reflect Galderma's own reporting and industry coverage of the July 2026 FDA update. Individual treatment response varies, and this information is not a promise of results.
What Just Happened With Relfydess
Relfydess is Galderma's ready-to-use liquid version of botulinum toxin type A, built on what the company calls PEARL technology, a manufacturing process meant to keep the toxin stable as a liquid so injectors can skip the mixing and reconstitution step used with older powder-based products. Early data the company has shared points to a fast onset for many patients, with roughly a third to just under 40 percent noticing a treatment effect within a day of injection, according to Galderma's own reporting.
The catch, for now, is that none of this applies in the United States. Around the start of July 2026, Galderma announced that the FDA issued a Complete Response Letter for the product's Biologics License Application, which means the agency is not ready to approve it for U.S. sale. This is the second time the application has been sent back since Galderma's original 2023 submission.
Why the FDA Sent It Back, Again
According to Galderma and industry coverage of the letter, the sticking point is not the toxin itself. The FDA's feedback centered on observations from a facility inspection and questions about analytical testing methods used to verify the product during manufacturing. Galderma has stated plainly that the safety and effectiveness sections of its application were not flagged.
That is a meaningfully different situation than a rejection over patient outcomes. Manufacturing-related Complete Response Letters typically require a company to fix production or testing processes and demonstrate the fix to inspectors, which can take additional months, rather than redesigning the product or running new clinical trials. Galderma has said resolving the U.S. path remains a priority and that it is working through corrective steps with the agency.
It's also worth noting this product has cleared the bar elsewhere. Relfydess already holds approval in roughly 33 markets and has launched commercially in more than 20 of them, with clinics offering it across a mix of regions that span the UK and continental Europe, several Asian and Middle Eastern countries, plus Australia. Galderma has described the international rollout as having an encouraging early trajectory, though that experience abroad doesn't shortcut the separate U.S. review process.
What This Means If You're Booking Injectables in Las Vegas
Practically speaking, nothing changes for anyone getting neurotoxin injections at a licensed med spa here this week. Relfydess simply isn't an option on any legitimate U.S. treatment menu right now, so there's no risk of it showing up in a syringe locally. What does change is the news cycle around it, since headlines about a hot new import can sometimes prompt curious clients to ask their provider if it's available.
If you do bring it up during a consult, a licensed provider should be able to explain plainly that it's still pending FDA clearance and walk you through which neuromodulators are actually approved and stocked in the U.S. today, such as the established onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and prabotulinumtoxinA products already on the market. None of those are affected by Relfydess's regulatory timeline.
- Ask your provider which brand and lot of toxin they're using before treatment, not just the general category.
- Confirm the product has current FDA clearance for the specific use you're discussing.
- Treat any 'not yet available here' product claims with healthy skepticism until you've verified them independently.
- Remember that international approval and U.S. approval are separate processes with different timelines and requirements.
The Bigger Picture: Ready-to-Use Formulas Are a Growing Category
Relfydess is part of a broader shift in how neuromodulators are being manufactured across the industry. For years, most botulinum toxin products shipped as a powder that a provider reconstituted with saline shortly before injection, a step that introduces some variability in dilution and timing. Ready-to-use liquid formats aim to remove that step entirely, which manufacturers argue can support more consistent dosing from vial to vial.
Whether or not Relfydess itself reaches U.S. clinics soon, expect more manufacturers to chase this format over the next few years. For clients, the practical takeaway is simple: newer isn't automatically better or available, and the right question to ask a licensed provider is always which specific, FDA-cleared products they're using and why they recommend one over another for your goals.
6 Things to Know Before You Ask About a 'New' Toxin at Your Med Spa
Regulatory headlines about injectables move fast and get simplified along the way. Here's a quick, plain-language rundown to keep in mind the next time a new product name comes up in conversation.
- It isn't legally available in the U.S. yet: Relfydess cannot be lawfully purchased, stocked, or injected in American clinics until the FDA clears the outstanding manufacturing questions.
- The hold-up is the factory, not the formula: Galderma has said the safety and efficacy portions of its application were not the issue, the letter centered on manufacturing inspection findings.
- Established toxins are unaffected: Neuromodulators already approved and sold in the U.S. continue on as normal and are not touched by this delay in any way.
- Ready-to-use liquid formats are a growing trend: More manufacturers are moving away from powder-and-reconstitute formats toward premixed liquid versions to reduce dosing variability.
- Approved overseas doesn't mean approved here: A product can be sold in dozens of countries and still be years away from a U.S. launch because each regulator runs its own separate review.
- Always ask what's actually in the syringe: A reputable, licensed provider will name the specific product and confirm its U.S. clearance status without hesitation if you ask.
Frequently Asked Questions
Is Relfydess available at any med spa in Las Vegas right now?
No. It has not received FDA approval for U.S. sale, so no legitimate licensed provider in the country, including here in Las Vegas, can legally offer it yet.
Does this FDA letter mean the product is unsafe?
According to Galderma's own statements, the letter centered on manufacturing and testing observations, not on safety or effectiveness concerns raised in the clinical data. That said, questions about any injectable's safety profile are always best directed to a licensed medical provider.
What neurotoxins can I actually get injected today?
Several FDA-approved neuromodulators are already on the market and widely used at licensed U.S. med spas. A consult with a licensed provider is the right place to discuss which one, if any, fits your goals.
When might Relfydess reach the U.S. market?
There's no confirmed timeline. Manufacturing-related delays like this one can resolve in months or stretch on longer depending on how quickly the company addresses the FDA's findings, so it's not something we can promise a date for.